Inhibition of the Wnt/β-Catenin Pathway Overcomes Resistance to Enzalutamide in Castration-Resistant Prostate CancerZhuangzhuang Zhang, Xiaoqi Liu, Lijun Cheng et al.|Cancer Research|2018Cited by 154
p300/CBP inhibition enhances the efficacy of programmed death-ligand 1 blockade treatment in prostate cancerJinghui Liu, Xiaoqi Liu, Karrie L. Jones et al.|Oncogene|2020Cited by 114
Inhibition of cholesterol biosynthesis overcomes enzalutamide resistance in castration-resistant prostate cancer (CRPC)Yifan Kong, Xiaoqi Liu, Lijun Cheng et al.|Journal of Biological Chemistry|2018Cited by 103
Inhibition of enhancer of zeste homolog 2 (EZH2) overcomes enzalutamide resistance in castration-resistant prostate cancerYunfeng Bai, Xiaoqi Liu, Zhuangzhuang Zhang et al.|Journal of Biological Chemistry|2019Cited by 83
Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint TherapyZhuangzhuang Zhang, Xiaoqi Liu, Lijun Cheng et al.|Cancer Research|2022Cited by 68